News: Canada

Here are your up-to-date news results!
Clicking the title of the article will give you the original publication.
You can share an article quickly with colleagues via Twitter and LinkedIn!

Latest thinking and events

FDA Approves First Generics of Gilenya
Published: 5 Dec 2019 | 22:12 UTC

December 05, 2019 -- The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients. “Approving safe...

Biogen divulges more data on Alzheimer’s trials
Published: 5 Dec 2019 | 19:14 UTC

Biotech’s shares fluctuate as it tries to win over sceptics of aducanumab

Annual Reported Measles Incidence Dropped From 2000 to 2018
Published: 5 Dec 2019 | 19:00 UTC

THURSDAY, Dec. 5, 2019 -- The annual reported measles incidence decreased from 2000 to 2018, but the number of cases increased from 2016 to 2018, according to research published in the Dec. 6 issue of the U.S. Centers for Disease Control and...

More Than 100 E. Coli Illnesses Now Linked to Romaine Lettuce
Published: 5 Dec 2019 | 19:00 UTC

THURSDAY, Dec. 5, 2019 -- Federal health officials are currently investigating a multistate outbreak of Escherichia coli infection linked to romaine lettuce thought to be grown in Salinas, California. Case numbers have risen from 67 reported a week...

Seven Deaths in California From Infections Tied to Black Tar Heroin
Published: 5 Dec 2019 | 19:00 UTC

THURSDAY, Dec. 5, 2019 -- Infections linked to injections of black tar heroin have killed seven people in San Diego County in the past two months, health officials said Wednesday. Between Oct. 2 and Nov. 24, nine adults, aged 19 to 57 years, were...

Evidence Uncertain Whether Interventions Prevent Falls in MS
Published: 5 Dec 2019 | 19:00 UTC

THURSDAY, Dec. 5, 2019 -- There is uncertainty regarding the effect of exercise and other interventions on the prevention of falls in patients with multiple sclerosis (MS), according to a review published online Nov. 28 in the Cochrane Database of...

Daily Cannabis Use Tied to Lower Illicit Opioid Use for Chronic Pain
Published: 5 Dec 2019 | 19:00 UTC

THURSDAY, Dec. 5, 2019 -- Individuals with chronic pain who use daily cannabis have lower odds of using illicit opioids, according to a Canadian study published online Nov. 19 in PLOS Medicine. Stephanie Lake, from University of British Columbia in...

FSD Pharma to Present at 12th Annual LD Micro Main Event Investor Conference on December 11
Published: 5 Dec 2019 | 0:00 UTC

The conference will be held December 10-12, 2019. Dr. Brennan will also host one-on-one meetings with investors throughout the day.

Venus Concept Inc. Announces CE Mark and Australian Regulatory Approval for NeoGraft 2.0, A Trusted Name in Hair Restoration
Published: 5 Dec 2019 | 0:00 UTC

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received a CE Mark from DEKRA Certification B.V. and Therapeutic Goods Administration (TGA) clearance in Australia to market NeoGraft 2.0 for hair restoration.

Algernon Pharmaceuticals’ NP-120 (Ifenprodil) Outperforms Merck’s Phase 3 Drug MK-7264 (Gefapixant) in an Acute Cough Study by 110%
Published: 5 Dec 2019 | 0:00 UTC

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company, is pleased to announce that NP-120, its repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis, showed dramatic superiority over Gefapixant, Merck’s lead phase 3 trial drug, in a well accepted acute cough in-vivo animal study.

Avivagen Receives Approval for Use of OxC-beta™ Livestock in Malaysia
Published: 5 Dec 2019 | 0:00 UTC

Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it has received approval for the use of OxC-beta™ Livestock in Broilers and Swine in Malaysia

MolecuLight Receives FDA 510(k) Clearance for its i:X® Handheld Fluorescence Imaging Device for Wound Management
Published: 5 Dec 2019 | 0:00 UTC

New FDA Approval Extends Label to Including the i:X's Detection of Bacteria and Digital Wound Measurement

Tully Luxury Travel Generously Supports CANFAR's Bloor Street Entertains for Third Consecutive Year
Published: 5 Dec 2019 | 0:00 UTC

Mary Jean Tully, Founder and CEO of Tully Luxury Travel (TLT) was honored to celebrate the third year of a five-year commitment she has made on behalf of TLT to CANFAR's Bloor Street Entertains on November 27th.

Trump administration willing to drop USMCA pharma provisions
Published: 4 Dec 2019 | 7:09 UTC

Bid to win support from Democrats in deal seen as template for future negotiations

How pot stocks lost their highs
Published: 4 Dec 2019 | 4:00 UTC

Momentum has stalled in key markets such as New York, New Jersey and Connecticut

Hogan Lovells obtains dismissal of all remaining charges against former New York State Assemblyman
Published: 3 Dec 2019 | 0:00 UTC

2 December 2019 – A New York State Supreme Court judge in Manhattan has dismissed all remaining charges against former New York State Assemblyman Alec Brook-Krasny in a long-running...

Tories can’t be trusted to look after the NHS | Letters
Published: 1 Dec 2019 | 18:25 UTC

Only Labour’s policies can help solve the healthcare crisis, write 12 nurses. Plus, Dr Robert Oulton says NHS England’s latest reorganisation needs scrutiny, Fiona Henderson worries about price rises in a drug crucial for her husband, and Dr Andrew Hill offers ideas on how to protect the NHS in UK-US trade deals

We are frontline nurses who have faced the reality of government mismanagement over the disastrous years of coalition and Conservatism.

The outlandish and widely ridiculed promise from the Conservatives to recruit 50,000 more nurses (If voters think all politicians lie, then the Tories win, Journal, 30 November) would be unnecessary had they not spent the last nine years driving services and staff to breaking point. Tens of thousands of nursing posts remain vacant, impacting severely on the quality of care our patients deserve. Our colleagues face unprecedented levels of stress and distress in their work, with little support or insight from government.

Continue reading...

There’s a simple way to protect the NHS from US trade negotiators | Emily Jones
Published: 1 Dec 2019 | 14:45 UTC

Pass a law stating the health service is not on the table – this would allow UK negotiators to declare the whole area off limits

No wonder there is alarm when we hear the NHS is on the negotiating table in UK-US talks. In the US, citizens struggle to afford their prescriptions, and medical bills are so high that they are a leading cause of bankruptcy. The US spends more per person on medicines than anywhere else in the world.

The US pharmaceutical industry is large and politically powerful, and the US uses trade deals to pressure other countries to follow its approach to regulation. Throughout this election the Conservative party has made repeated claims that “the NHS is off the negotiating table”, but has not followed up with any efforts to turn this promise into reality.

Related: A US trade deal could cost the NHS tens of millions. My investigation shows how | Antony Barnett

Continue reading...

US biotech M&A: gene genies
Published: 29 Nov 2019 | 15:00 UTC

Rewards can be dazzling when Big Pharma takes the bait

Innovative finance schemes increase access to medicine
Published: 29 Nov 2019 | 4:30 UTC

Bulk purchasing guarantees help overcome manufacturers’ reluctance

FT Health: Innovation in Healthcare
Published: 29 Nov 2019 | 4:30 UTC

FT writers examine technical and policy developments that could have a real impact in the drive for universal health coverage, from drone initiatives in Malawi to new finance mechanisms that ‘de-risk’ deals for companies producing medical supplies for poorer countries

A further step towards an EU-wide collective action
Published: 28 Nov 2019 | 0:00 UTC

Today representatives of EU member states agreed on a mutual position regarding the Commission's Proposal for a Directive on representative actions for the protection of the collective...

The Guardian view on Boris Johnson and the NHS: a problem of trust | Editorial
Published: 27 Nov 2019 | 18:56 UTC

The prime minister’s promise to protect the health service in trade talks is made worthless by his record of lies and broken pledges

Whether Conservatives can be trusted with the NHS is an old question at election time. Whether Boris Johnson can be trusted on anything is an issue for the current campaign. The two questions make a dangerous combination for the Tory leader, who is expecting the country to believe that he would protect the health service in a post-Brexit trade deal with Donald Trump.

There is not much reason to believe that he would. On Wednesday Labour sought to probe that concern, revealing documents containing a full account of preliminary discussions between US and UK officials.

Continue reading...

FDA delays draft rule for QSR/ISO 13485 harmonization
Published: 25 Nov 2019 | 0:00 UTC

The U.S. Food and Drug Administration (FDA) indicated that the long-anticipated proposed rule modernizing the Quality System Regulation (QSR) is now targeted for release in April 2020.

Data class actions guide
Published: 21 Nov 2019 | 0:00 UTC

Does your processing of personal data fall within the scope of the GDPR? Are you ready to defend potential data-related litigation – in particular, data class actions?

It took the cystic fibrosis community years to win this lifesaving drug. It can’t be taken away | Isabelle Jani-Friend
Published: 20 Nov 2019 | 15:09 UTC

Orkambi, once too expensive for the NHS, has brought hope to thousands. A new UK-US trade deal could see its price rise again

For the first time in my life I now feel able to consider a more fulfilled and “normal” life. Picking up a cold and ending up in hospital may no longer be my reality and the thought of reaching middle-age seems more realistic. This follows the huge victory of cystic fibrosis patients and the parents of children with the condition to get access to life-changing drugs on the NHS across the UK.

I was diagnosed with cystic fibrosis when I was six. I’m now 21, and since then have been under a strict medical regime which sees me spend three hours a day undergoing treatment; a combination of 30 tablets a day, inhaled medications and constant physiotherapy. Despite my daily routine, I also get admitted into hospital when I pick up a lung infection, leaving me in a hospital isolation room for two weeks at a time. This takes me away from my family and friends, and has had a huge impact on my education and work opportunities.

The years of struggle by people with CF to gain access to these drugs has taken its toll

Continue reading...

Hogan Lovells represents LabCorp in an offering of over US$1billion in senior notes and a concurrent US$300 million cash tender offer
Published: 20 Nov 2019 | 0:00 UTC

New York, 20 November 2019 – Global law firm Hogan Lovells is representing LabCorp, a leading global life sciences company, in an offering of over US$1 billion principal amount of senior...

Heather Ashton obituary
Published: 18 Nov 2019 | 17:28 UTC

Psychopharmacologist who started a clinic for people addicted to tranquillisers and wrote a manual on how to quit them safely

One day in the early 1980s a distressed patient went to see the doctor Heather Ashton at her pharmacology clinic in the Royal Victoria hospital, Newcastle upon Tyne.

The patient had been given the tranquilliser Ativan (lorazepam) to relax her muscles before an operation and now feared she was addicted to the drug. Ashton listened to her patient and many others like her, studied their problems scientifically, and concluded that addiction to benzodiazepine tranquillisers was a serious problem, associated with severe withdrawal symptoms. The manual she went on to write on how to quit benzodiazepines safely now provides the basis for practice all over the world.

Continue reading...

Revealed: NHS running short of dozens of lifesaving medicines
Published: 18 Nov 2019 | 6:00 UTC

Internal document seen by the Guardian shows low supplies for heart, cancer and anti-epilepsy drugs

The NHS is running short of dozens of lifesaving medicines including treatments for cancer, heart conditions and epilepsy, the Guardian has learned.

An internal 24-page document circulated to some doctors last Friday from the medicine supply team at the Department of Health and Social Care (DHSC), headed “commercial-sensitive”, listed many drugs currently hit by shortages at the NHS.

Related: Brexit ‘already causing medicine shortages’ at pharmacies in England

Cyanide poisoning drug: the sole supplier is experiencing long term out of stock issues.

Diamorphine: “insufficient stock to cover full forecasted demand in both primary and secondary care”.

Anti-epilepsy drug: “Patients should normally be maintained on the same brand. However … will be out of stock … until March 2020”.

Tuberculosis medication: two suppliers are out of stock, a third has some stock “but is unable to support any uplift in demand”.

Dementia drug: need to change type and frequency of dose, which could be confusing for dementia patients.

Continue reading...

Please note that GR Consulting can not alter or influence the messages displayed, nor is it responsible for its content. If needed or desired, please refer to the original message and/or its originator.